NFKBIL1 Antibody (A-6): sc-518229

NFKBIL1 Antibody (A-6) is a mouse monoclonal IgG1 kappa light chain antibody specific for an epitope mapping between amino acids 220-246 of NFKBIL1 of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). NFKBIL1 monoclonal antibody (A-6) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The NFκB inhibitor-like protein 1 (NFKBIL1), also known as IKBL, plays a crucial role as a negative regulator of NFκB activation, which is essential for controlling inflammatory responses and immune system regulation. By inhibiting NFκB, NFKBIL1 helps maintain cellular homeostasis and prevent excessive inflammation, making NFKBIL1 vital for the prevention of autoimmune diseases and other inflammatory disorders. Mutations in the NFKBIL1 gene have been associated with several conditions, including type 1 diabetes, rheumatoid arthritis, ulcerative colitis, and chronic Chagas cardiomyopathy, highlighting NFKBIL1′s importance in maintaining immune balance and potential as a therapeutic target. Anti-NFKBIL1 antibody (A-6) serves as a valuable tool for studying the regulation of NFκB activity and its implications in immune function and inflammatory disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NFKBIL1 Antibody (A-6) References:

1. Sequence analysis and expression of a mouse homolog of human IkappaBL gene.  |  Handel-Fernandez, ME. and Vincek, V. 1999. Biochim Biophys Acta. 1444: 306-10. PMID: 10023090
2. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL.  |  de la Concha, EG., et al. 2000. Gastroenterology. 119: 1491-5. PMID: 11113070
3. IKBL promoter polymorphism is strongly associated with resistance to type 1 diabetes in Japanese.  |  Yamashita, T., et al. 2004. Tissue Antigens. 63: 223-30. PMID: 14989711
4. Direct determination of single nucleotide polymorphism haplotype of NFKBIL1 promoter polymorphism by DNA conformation analysis and its application to association study of chronic inflammatory diseases.  |  Shibata, H., et al. 2006. Hum Immunol. 67: 363-73. PMID: 16720219
5. Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative.  |  Ruben, SM., et al. 1992. Mol Cell Biol. 12: 444-54. PMID: 1732726
6. Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans.  |  Koch, W., et al. 2007. Hum Mol Genet. 16: 1821-7. PMID: 17517687
7. Variants in the promoter region of IKBL/NFKBIL1 gene may mark susceptibility to the development of chronic Chagas' cardiomyopathy among Trypanosoma cruzi-infected individuals.  |  Ramasawmy, R., et al. 2008. Mol Immunol. 45: 283-8. PMID: 17544510
8. Functional characterization of NF-kappaB inhibitor-like protein 1 (NFkappaBIL1), a candidate susceptibility gene for rheumatoid arthritis.  |  Greetham, D., et al. 2007. Hum Mol Genet. 16: 3027-36. PMID: 17855452
9. Association study between the -62A/T NFKBIL1 polymorphism and obsessive-compulsive disorder.  |  Cordeiro, Q., et al. 2009. Braz J Psychiatry. 31: 131-5. PMID: 19578685
10. NFKBIL1 confers resistance to experimental autoimmune arthritis through the regulation of dendritic cell functions.  |  Chiba, T., et al. 2011. Scand J Immunol. 73: 478-85. PMID: 21284685
11. Associations between autistic-like traits and polymorphisms in NFKBIL1.  |  Strenn, N., et al. 2019. Acta Neuropsychiatr. 31: 220-229. PMID: 31162003
12. Genomic organization of the gene encoding the p65 subunit of NF-kappa B: multiple variants of the p65 protein may be generated by alternative splicing.  |  Deloukas, P. and van Loon, AP. 1993. Hum Mol Genet. 2: 1895-900. PMID: 8281153

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-NFKBIL1 Antibody (A-6) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-NFKBIL1 Antibody (A-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

NFKBIL1 Antibody (A-6) Specifications

Alternate Product Name: NFKBIL1

Product Clone Name: A-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 220-246

Epitope Target: NFKBIL1

Epitope Species: human

Product Reactivity/Detection: NFKBIL1

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for NFKBIL1 Antibody (A-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin